.png)
Minimally Invasive Surgery (MIS) for Sacroiliac (SI) Joint Fusion is a procedure designed to treat sacroiliac joint dysfunction and chronic lower back pain. It involves the use of small incisions, image-guided navigation, and specialized implants or screws to stabilize the SI joint. The rise in demand for outpatient procedures, aging population, and technological advances in orthopedic surgery have significantly boosted the adoption of MIS SI joint fusion techniques.
As of 2025, over 95,000 MIS SI joint fusion procedures are projected to be performed globally, marking a 9% increase from 2024. The adoption of outpatient surgery centers (ASCs) for these procedures has also increased, now accounting for 38% of total surgeries.
MIS Sacroiliac Joint Fusion Market reached a valuation of USD 327.7 million in 2023 and is anticipated to expand significantly, expected to reach USD 398.5 million in 2024, ultimately soaring to USD 1,902.1 million by 2032. This growth reflects a robust CAGR of 21.58%
How Big is the MIS Sacroiliac Joint Fusion Industry in 2025?
The global MIS SI joint fusion industry is expected to witness the installation of over 300,000 implants in 2025, up from 270,000 in 2024. The shift toward patient-specific implants, AI-guided navigation, and robotic-assisted techniques is accelerating growth.
In the U.S. alone, more than 57,000 procedures are expected in 2025, driven by a rise in lower back pain prevalence, which affects nearly 28% of the adult population annually. Demand is particularly high in outpatient care, with ASC-based surgeries growing 15% year-on-year.
USA Growing MIS Sacroiliac Joint Fusion Market
The United States continues to lead in the MIS SI joint fusion market, both in terms of innovation and adoption. As of 2025:
- The U.S. represents approximately 60% of all global MIS SI fusion procedures.
- 31,000+ devices are expected to be implanted in outpatient settings.
- Medicare reimbursement policies have expanded to include newer fusion systems, increasing procedural accessibility.
- There is a 12% rise in orthopedic outpatient center investments, indicating growing support infrastructure.
Impact of U.S. Tariffs on the MIS Sacroiliac Joint Fusion Market
The U.S. medical device ecosystem, including components used in MIS sacroiliac joint fusion procedures—such as surgical-grade fasteners, titanium implants, and stainless steel screws—has been impacted by evolving tariff structures, especially those tied to Section 301 tariffs on Chinese imports and Section 232 tariffs on steel and aluminum.
Tariff-Driven Pressure Points:
- Steel and Aluminum Tariffs (Section 232): Imposed in 2018, these tariffs added 25% on steel and 10% on aluminum imports. This directly impacted the cost of orthopedic screws and fixation devices, a critical component in MIS SI joint fusion.
- Section 301 Tariffs on Chinese Goods: Starting 2019, many precision components used in medical fasteners and surgical tools faced up to 25% additional tariffs if sourced from China.
Market-Level Impacts:
- Cost Inflation: Between 2020 and 2024, the average cost of SI joint fusion hardware kits (screws, plates, guides) increased by 7–9%, partly due to higher landed costs of materials and components.
- Sourcing Shift: U.S.-based OEMs like The Hillman Group and Grip-Rite began shifting sourcing and manufacturing to Taiwan, Vietnam, and Mexico, resulting in a 15–20% reduction in tariff-exposed inputs by 2024.
- Procedure Economics: Higher costs have marginally impacted provider margins, especially at Ambulatory Surgical Centers (ASCs), where bundled reimbursement rates are tighter. According to MedPAC data, average cost per procedure increased by ~$320 in facilities sourcing tariff-impacted fasteners.
Company Strategy Response:
- Würth Group increased investment in intra-European production and distribution centers, reducing U.S. exposure to tariff volatility.
- Fu Yeh and ZYH YIN (Taiwan) became key suppliers to U.S. orthopedic brands, with orders increasing 22% YoY in 2024 due to tariff avoidance strategies.
- SENCO and Triangle Fastener reported accelerated domestic production timelines and engaged in material substitutions (e.g., titanium-aluminum alloys) to mitigate steel-related costs.
Regulatory Buffering:
- The U.S. Trade Representative (USTR) granted limited product exclusions for certain surgical-grade titanium screws, especially those with ISO 13485 certifications, reducing exposure for some companies—but these exclusions were temporary and expired in Q3 2023.
Regional Market Share and Opportunities
- North America: Holds 60% market share, with the U.S. as a clear leader. Growth opportunities lie in outpatient clinics and hospital affiliations.
- Europe: Accounts for 20% of the market, led by Germany, France, and the U.K. Efforts are focused on cost-efficient minimally invasive devices.
- Asia Pacific: Holds 12% share but offers high growth potential due to increased hospital infrastructure investments in India, China, and Japan.
- Latin America and MEA: Combined share of 8%, with Brazil and South Africa seeing gradual uptake due to improved orthopedic training programs and growing middle-class healthcare expenditure.
Opportunities:
- AI-based surgical planning tools
- Patient-specific implants with 3D printing
- Cross-border telehealth consultation for post-op recovery monitoring
Global Growth Insights unveils the top List global MIS Sacroiliac Joint Fusion Companies:
| Company | Headquarters | 2024 Revenue (USD) | Estimated CAGR |
|---|---|---|---|
| Würth Group | Künzelsau, Germany | $22.5 billion | 6.2% |
| Grip-Rite | Grand Prairie, Texas, USA | $680 million | 5.5% |
| Fu Yeh | Taichung, Taiwan | $135 million | 4.9% |
| Katsuhana Fasteners | Osaka, Japan | $92 million | 4.5% |
| The Hillman Group | Cincinnati, Ohio, USA | $1.4 billion | 6.7% |
| Triangle Fastener Corporation | Pittsburgh, Pennsylvania, USA | $180 million | 4.6% |
| SENCO | Cincinnati, Ohio, USA | $410 million | 5.2% |
| H. PAULIN | Ontario, Canada | $220 million | 4.3% |
| National Nail | Grand Rapids, Michigan, USA | $195 million | 4.9% |
| ZYH YIN | Tainan, Taiwan | $72 million | 3.8% |
Conclusion: Future Pathways for MIS Sacroiliac Joint Fusion Companies
The MIS sacroiliac joint fusion market in 2025 is poised for sustained growth due to increased demand for minimally invasive care, particularly in outpatient and home-based recovery settings. Companies offering reliable fasteners, innovative bio-compatible materials, and integration with robotic systems are likely to lead market share.
While the U.S. remains the epicenter of MIS SI fusion, emerging markets such as India, Brazil, and Southeast Asia offer fertile ground for scalable and cost-effective surgical solutions. Players like Würth, Hillman, and Grip-Rite are positioning themselves to address these opportunities with agile supply chains and R&D collaborations.
Overall, the market is moving toward a future where precision, miniaturization, and personalized implants define competitive advantage—and companies that invest in integrated surgical ecosystems will be best positioned to capture the next wave of innovation.